Evidence for SGLT-2 inhibitors: A systematic review and meta-analysis (13 studies, n=90413) reported that SGLT-2 inhibitors reduced the risk of renal disease progression by 37% (RR: 0.63, 95% CI (0.58-0.69)) and acute kidney injury by 23% (0.77, 0.70-0.84) in individuals with and without T2D [89]. Here, SLC5A2 is linked to acute kidney injury.